BiotechTube

Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pelvic Pain

Conditions

Pelvic Pain

Trial Timeline

Jun 1, 2024 → Nov 2, 2025

NCT ID
NCT06279195

About Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet

Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet is a phase 2 stage product being developed by Pfizer for Pelvic Pain. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06279195. Target conditions include Pelvic Pain.

What happened to similar drugs?

3 of 6 similar drugs in Pelvic Pain were approved

Approved (3) Terminated (1) Active (3)
✅Solifenacin + PlaceboAstellas PharmaApproved
🔄AzithromycinPfizerPhase 3
✅Conjugated Estrogens Cream + Placebo CreamPfizerApproved
🔄Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)BayerPhase 3
🔄Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3
✅Sevoflurane + propofol + remifentanilBaxterApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06279195Phase 2Withdrawn

Competing Products

11 competing products in Pelvic Pain

See all competitors
ProductCompanyStageHype Score
Solifenacin + PlaceboAstellas PharmaApproved
35
BGS649 + PlaceboNovartisPhase 2
27
Tanezumab + PlaceboPfizerPhase 2
35
AzithromycinPfizerPhase 3
40
Vaginal estrogen + PlaceboPfizerPre-clinical
18
Conjugated Estrogens Cream + Placebo CreamPfizerApproved
43
BAY1834845 + PlaceboBayerPhase 1
26
Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)BayerPhase 3
37
Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3
37
Dienogest (BAY86-5258, Visanne)BayerPre-clinical
23
Sevoflurane + propofol + remifentanilBaxterApproved
40